[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 14, 1994

Management of Adverse Reactions to Trimethoprim-Sulfamethoxazole in Human Immunodeficiency Virus—Infected Patients

Author Affiliations

From the Department of Medicine, University of Washington, Seattle.

Arch Intern Med. 1994;154(21):2402-2406. doi:10.1001/archinte.1994.00420210028004

Trimethoprim-sulfamethoxazole is an important medication for the treatment and prevention of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Use of this medication has been limited by the high frequency of adverse reactions that occur in patients with human immunodeficiency virus disease. This article reviews the incidence and spectrum of adverse reactions and options for continuing therapy with trimethoprim-sulfamethoxazole in human immunodeficiency virus—infected patients who have adverse reactions. (Arch Intern Med. 1994;154:2402-2406)